Intravenous immunoglobulin maintenance treatment in myasthenia gravis: A randomized, controlled trial sample size simulation
- 30 October 2014
- journal article
- research article
- Published by Wiley in Muscle & Nerve
- Vol. 50 (6) , 999-1004
Abstract
Introduction: In cases of exacerbation or crisis, myasthenia gravis (MG) patients can be treated with intravenous immunoglobulin (IVIg), plasmapheresis, or immunoadsorption. However, IVIg efficacy data in maintenance treatment are sparse. Methods: We prospectively observed 16 index patients with chronic and insufficiently controlled MG under standard immunosuppressant therapy and symptomatic treatment. The IVIg treatment response was measured using changes in quantitative myasthenia gravis (QMG) score and surrogates. Based on these results, a sample size calculation for a future randomized, controlled trial (RCT) was simulated. Results: There was an enduring decline in QMG score and other parameters of about 50% under IVIg maintenance treatment. RCT sample size calculation results in 73 or 33 patients per arm to detect at least a 20% vs. 30% clinical difference in QMG score. Conclusion: We recommend using the QMG score as a primary endpoint for an RCT of IVIg maintenance for chronic MG. Muscle Nerve, 2014Keywords
Funding Information
- F�rderverein Neurologie e. V. (BT - 07/2010)
This publication has 34 references indexed in Scilit:
- Guidelines for treatment of autoimmune neuromuscular transmission disordersEuropean Journal of Neurology, 2010
- Review: Progress in the treatment of myasthenia gravisTherapeutic Advances in Neurological Disorders, 2008
- Disease‐specific measure of quality of life for myasthenia gravisMuscle & Nerve, 2008
- Rebooting the Immune System with High‐Dose Cyclophosphamide for Treatment of Refractory Myasthenia GravisAnnals of the New York Academy of Sciences, 2008
- IVIG Treatment for Myasthenia GravisAnnals of the New York Academy of Sciences, 2008
- IV immunoglobulin in patients with myasthenia gravisNeurology, 2007
- Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravisMuscle & Nerve, 2002
- Reliability Testing of the Quantitative Myasthenia Gravis ScoreaAnnals of the New York Academy of Sciences, 1998
- Immunosuppressive Treatments: Their Efficacy on Myasthenia Gravis Patients' Outcome and on the Natural Course of the DiseaseaAnnals of the New York Academy of Sciences, 1993
- ALTERNATE‐DAY PREDNISONE: PRELIMINARY REPORT OF A DOUBLE‐BLIND CONTROLLED STUDY*Annals of the New York Academy of Sciences, 1976